| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.05 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.05 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.06 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.06 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.06 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |